An FDA advisory committee will hear divergent opinions on appropriate efficacy endpoints for investigational treatments of secondary hypogonadism at a Dec. 6 meeting.
FDA's Bone, Reproductive and Urologic Drugs Advisory Committee will discuss appropriate clinical trial design features, including acceptable endpoints for demonstrating...




